PPARG and metabolic disease: PIO and MSCs have been shown to inhibit fibrosis and PPARs have already been considered an attractive therapeutic target for the treatment of metabolic disorders and PPARγ agonists were shown to effectively attenuate oxidative stress, inflammation and apoptosis6.